Proteasome Inhibitor News and Research

RSS
Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

FDA ODAC votes in favor of Onyx’s Kyprolis

FDA ODAC votes in favor of Onyx’s Kyprolis

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

Three-drug regimen provides rapid, durable responses for multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

SLU investigator aims to reduce chemotherapy-induced peripheral neuropathy

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Biochemists determine first crystal structure of an immunoproteasome

Biochemists determine first crystal structure of an immunoproteasome

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Onyx announces data from three carfilzomib studies on RRMM

Onyx announces data from three carfilzomib studies on RRMM

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment